

**NEUROENDOCRINE CANCER UK**  
**PREVIOUSLY NET PATIENT FOUNDATION**  
**ANNUAL REPORT AND UNAUDITED FINANCIAL STATEMENTS**  
**FOR THE YEAR ENDED 30 SEPTEMBER 2020**

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
LEGAL AND ADMINISTRATIVE INFORMATION**

---

**Trustees** Mr P Gwilliam (Chairman)  
Mr D Jones  
Mrs M Phillips  
Mrs R Littlejohn  
Dr R Srirajaskanthan  
Mrs I Wotherspoon

**Charity number** 1092386

**Principal address** Second Floor  
Holly House  
74 Upper Holly Walk  
Leamington Spa  
Warwickshire  
CV32 4JL

**Independent examiner** Chapman Worth Limited  
3 The Old Estate Yard  
High Street  
East Hendred  
Wantage  
Oxfordshire  
OX12 8JY

**Bankers** Lloyds Bank  
Butler Place Branch  
PO Box 100  
BX1 1LT

---

# NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION CONTENTS

---

	<b>Page</b>
Trustees' report	1 - 4
Independent examiner's report	5
Statement of financial activities	6
Statement of financial position	7
Notes to the financial statements	8 - 21

---

# **NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT**

***FOR THE YEAR ENDED 30 SEPTEMBER 2020***

---

The trustees have the pleasure in presenting the Trustees' Report and Accounts of Neuroendocrine Cancer UK for the year ended 30 September 2020. The trustees are satisfied with the performance and progress of the charity during the year.

The accounts have been prepared in accordance with the accounting policies set out in note 1 to the accounts and comply with the Constitution of the charity, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016).

## **Objectives**

The constitutional Objects of the charity are set out later in this report.

Our Vision is of a world in which people know how to recognize, diagnose, treat, care for and ultimately cure patients with neuroendocrine cancer.

Our Mission is to support and inform patients and families from diagnosis enabling access to the best care and treatment whilst stimulating neuroendocrine research, increasing national awareness and influencing improvements in outcomes.

The Values we believe in are (i) equality of care for all NET patients in the UK (ii) excellence in support, care, treatment and research (iii) fair allocation of national resources and inclusion in national policies and strategies for all cancer types (iv) collaborative working and building an accessible approachable fraternity and (v) honesty, transparency and integrity to promote confidence and trust in the charity.

## **Terminology, Purpose and Need**

The umbrella name for neuroendocrine cancers was changed by the World Health Organisation in 2017 to neuroendocrine neoplasms (NENs), incorporating tumours and neuroendocrine carcinomas. NENs are a group of unusual and unpredictable tumours which develop from cells in the diffuse endocrine system. NENs can affect people of any age and can be benign (non-cancerous) or malignant (cancerous). Neuroendocrine Cancer UK supports patients with malignant NENs (neuroendocrine cancer) which are found most commonly in the lung or gastrointestinal system. Every year about 5,000 people are diagnosed with NENs in the UK with around 40,000 living with the disease. Incidence has increased from 4.6 per 100,000 to 8.7 per 100,000 recorded in 2016.

It is undoubtable that receiving a cancer diagnosis is traumatic and patients are often left in a state of shock, confusion, sadness and anxiety. For NEN patients specifically the prospect of a cure is often nil and remission unlikely. Unlike other cancers, even if there are no other signs of visible disease after treatment, there will be a point when the cancer returns.

As patients frequently wait too long for their diagnosis they can often be treated for the wrong disease meaning their cancer pathway begins with feelings of extreme frustration. At all stages of their treatment NEN patients are also less likely to receive written information about their cancer and its side effects. This is highlighted by the 2014 National Cancer Patient Survey which found that only half of neuroendocrine cancer patients were given written information about all of their tests compared with 91% of cancer patients in general.

# **NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)**

***FOR THE YEAR ENDED 30 SEPTEMBER 2020***

---

After treatment patients have to address the gravity of their diagnosis at home and often without regular access to the support of doctors and nurses. Therefore patients frequently suffer from feelings of abandonment and struggle to know who to confide in. Indeed, if their cancer is particularly advanced, they face the possibility of dying. From our experience the complexity of NENs means that patients, family and friends often struggle to comprehend their suffering.

People with a less common cancer like NENs are disadvantaged at every step of their cancer journey. From the speed of diagnosis through to treatment and research, people with rare cancers often receive a second-class service. It is time for a more consistent approach by ensuring that people are treated equally, that they get the specialist treatment they need and that they are properly supported to live their lives as fully as possible. Policy makers, health professionals and commissioners need to acknowledge the differences in patient experiences and to take positive and meaningful steps to address them.

## **Achievements and performance**

The most significant change in this year was the rebranding from NET Patient Foundation to Neuroendocrine Cancer UK. We changed our name to better reflect our community, building on the foundation we have laid down over the last 17 years (2002 – Living with Carcinoid, 2006 – NET Patient Foundation, 2020 – Neuroendocrine Cancer UK). We want to reduce confusion and increase awareness of this cancer type and by giving us a more focused and explanatory name we can better serve our community. The ethos and mission of the charity remain the same – to support all affected by neuroendocrine cancer, to support and inform patients and families from diagnosis, enabling access to the best care and treatment whilst stimulating neuroendocrine cancer research, increasing national awareness and influencing improvements in outcomes.

The CEO is supported by a full time specialist nurse and a team of administrative and communications staff. A dedicated group of patient ambassadors also support the work of the organization and two further ambassadors were added to the team this year.

- An all new website was launched with multimedia platforms, videos and animations.
- A new patient app/self management tool was completed and has gone into trial mode within eight centres of excellence looking at QOL amongst the community. This is supported by the NIHR.
- Our epidemiology work was published in the British Journal of Medicine and the next phase of the project has commenced.
- NCUK became a non commercial partner within NIHR.
- Our nurse course project – NCUK Academy – commenced with a launch date of July 2021.
- Two patient education events were held which was two less than planned due to the pandemic.
- The use of our psychotherapy service has continued to increase. A mindfulness course was put together and is free to use, but the 'living well' course had to be postponed until 2021.
- Our patient support groups – Natter groups – continue to develop but an online approach was adopted to support patients through the pandemic. 115 meetings have taken place to date.
- Development of the MIND the Gap Campaign continued alongside the launch of two further Gap campaigns: FIND the Gap and Bridging the Gap. A MIND the Gap report was commenced and is due for publication in March 2021.
- A free financial guidance service was developed together with a partnership with Bequeathed.com to develop our legacy work.
- Two major research surveys were undertaken: Covid and My Care and Barriers to Diagnosis. The Covid work is for presentation at the UKINETS national conference.
- Presentations at national and international meetings and teaching sessions for junior doctors, trainee GP's and the nursing community, mainly via online platforms.
- Our CEO continuing her work as President of the International Neuroendocrine Cancer Alliance.
- The NCUK community took part in the national 2.6 challenge in the summer of 2020.

# **NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)**

***FOR THE YEAR ENDED 30 SEPTEMBER 2020***

---

## **Note from the CEO Cathy Bouvier**

There are multiple components to running a patient organization. We are a 'small but vital' charity carrying out a wide range of activities, ensuring that the message we are shouting gets heard across many platforms, with the ultimate goal of working in a truly collaborative way, with compassion, and providing the best care for all affected by neuroendocrine cancer (NC). However there were significant challenges throughout this year with the global pandemic, loss of funds, remote working and an increase in the need for our support services. The helpline alone saw an increase in activity of 92.5%. The team pulled together however and there were many positive outputs, not least the remarkable community spirit. We have had to adapt and change our approaches, and some of these adaptations have certainly been positive ones that we will take forward into the new year.

## **Note from the Chair Peter Gwilliam**

On behalf of the trustees I confirm our delight in the growth of NCUK and the strengths of our team and all they are achieving. This is all under the direction of the co-founder and Chief Executive Cathy Bouvier who gives so much in her role across the 5 pillars of NCUK activity. Our thanks to you all and to the specialists, consultants and other helpers who give their time. We are of course totally dependent on grants and charitable donations and are so grateful to all our supporters.

This is also an opportunity to thank my fellow trustees for all their hard work in focusing on our vision, mission and values. The positive feedback received confirms that NCUK is making a big difference to so many lives. This report informs that we are certainly 'punching above our weight' and we will all continue to strive to achieve so much more.

## **Financial review**

The charity is totally reliant on the generous grants and charitable donations received from its supporters. The charity reported a surplus of £7,676 for the year which will be utilized during the following year in support of the objectives of the charity as set out earlier in this report.

Income raised during the year enabled the charity to meet its objectives. Expenditure on charitable activities during the year (see note 7) was within the planned financial framework agreed by the trustees.

At the reporting date the charity held funds of £473,087 and the trustees are satisfied that this level of funds will support the planned activities of the charity for the next 12 months. This level of reserves is in line with the reserves policy of the charity and ensures that it can prepare these accounts on a going concern basis with sufficient contingency if the level of grants and donations should fall during a period of increased economic uncertainty.

## **Structure, governance and management**

The NET Patient Foundation was established on 21 February 2001. It's governing document is a Constitution which was adopted on that date and has been amended on a number of occasions subsequently. On 25 June 2013 the name of the charity was shortened to NET Patient Foundation removing the words "incorporating Living with Carcinoid". On 12 December 2019 the name of the charity was changed to Neuroendocrine Cancer UK.

# **NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION TRUSTEES' REPORT (CONTINUED)**

***FOR THE YEAR ENDED 30 SEPTEMBER 2020***

---

The Objects of the charity were amended on 5 December 2013 to more simply reflect it's principal aims as follows:

- (i) To advance the education of the general public (including relevant medical and scientific communities) in all areas relating to NETs.
- (ii) To promote the physical and mental health of those affected by NETs through the provision of support, advice and education to patients, their carers and family members.

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new trustees.

The trustees have a range of skills and experience and they meet regularly with the CEO of the charity to develop strategy, discuss and agree objectives and subsequently to establish whether the strategy has been implemented and the objectives have been achieved.

The charity enlists the support of volunteers for various projects such as patient input into NCRI neuroendocrine sub-group meetings, national NCUK projects and awareness raising activities such as NET Cancer Day. It also uses a bank of consultants for PR and media support, and psychotherapy services for patients and family members.

In addition NCUK is supported by an expert Advisory Board which is an inter-disciplinary group of specialists (doctors, nurses and allied health care professionals including dieticians and counsellors) who all have a wealth of experience working with neuroendocrine cancer. This Board was established to provide expert advice, to promote and ensure effective, accessible, equitable and evidence-based health care and to provide information on current and future developments in neuroendocrine cancer care. The areas of clinical competence and expertise provided by members of this Board include primary, hospital and community care, pharmaceuticals, dietetics, research and development, health promotion and health education. Board members are based primarily but not exclusively in the fields of gastroenterology, surgery, endocrinology, radiology, nuclear medicine and oncology. Advisory Board members are on hand to answer any patient queries which the NCUK team cannot resolve.

The trustees confirm that they have followed the Charity Commission's general guidelines on public benefit in undertaking their activities. All trustees are aware of the Charity Commission Public Benefit Guidance (September 2013).

The Trustees who served during the year and up to the date of signature of the financial statements were:

Mr P Gwilliam (Chairman)

Mr D Jones

Mrs M Phillips

Mrs R Littlejohn

Dr R Srirajaskanthan

Mrs I Wotherspoon

The Board of Trustees is responsible for the overall management and control of the charity and for the appointment of new Trustees.

The trustees' report was approved by the Board of Trustees.

.....  
**Mr P Gwilliam (Chairman)**

Trustee

Dated: .....

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
INDEPENDENT EXAMINER'S REPORT  
TO THE TRUSTEES OF NEUROENDOCRINE CANCER UK**

---

I report to the Trustees on my examination of the financial statements of Neuroendocrine Cancer UK (the charity) for the year ended 30 September 2020.

**Responsibilities and basis of report**

As the Trustees of the charity you are responsible for the preparation of the financial statements in accordance with the requirements of the Charities Act 2011 (the 2011 Act).

I report in respect of my examination of the charity's financial statements carried out under section 145 of the 2011 Act. In carrying out my examination I have followed all the applicable Directions given by the Charity Commission under section 145(5)(b) of the 2011 Act.

**Independent examiner's statement**

Since the charity's gross income exceeded £250,000 your examiner must be a member of a body listed in section 145 of the 2011 Act. I confirm that I am qualified to undertake the examination because I am a member of ICAEW, which is one of the listed bodies.

Your attention is drawn to the fact that the charity has prepared financial statements in accordance with Accounting and Reporting by Charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102) in preference to the Accounting and Reporting by Charities: Statement of Recommended Practice issued on 1 April 2005 which is referred to in the extant regulations but has now been withdrawn.

I understand that this has been done in order for financial statements to provide a true and fair view in accordance with Generally Accepted Accounting Practice effective for reporting periods beginning on or after 1 January 2015.

I have completed my examination. I confirm that no matters have come to my attention in connection with the examination giving me cause to believe that in any material respect:

- 1 accounting records were not kept in respect of the charity as required by section 130 of the 2011 Act; or
- 2 the financial statements do not accord with those records; or
- 3 the financial statements do not comply with the applicable requirements concerning the form and content of accounts set out in the Charities (Accounts and Reports) Regulations 2008 other than any requirement that the accounts give a true and fair view which is not a matter considered as part of an independent examination.

I have no concerns and have come across no other matters in connection with the examination to which attention should be drawn in this report in order to enable a proper understanding of the financial statements to be reached.

Anna Chapman FCA  
Chapman Worth Limited  
3 The Old Estate Yard  
High Street  
East Hendred  
Wantage  
Oxfordshire  
OX12 8JY

Dated: .....



**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
STATEMENT OF FINANCIAL ACTIVITIES  
INCLUDING INCOME AND EXPENDITURE ACCOUNT  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

	Notes	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Total 2019 £
<b><u>Income from:</u></b>					
Donations and legacies	3	223,684	-	223,684	317,763
Grants	4	-	71,120	71,120	66,846
Investments	5	170	-	170	150
<b>Total income</b>		<u>223,854</u>	<u>71,120</u>	<u>294,974</u>	<u>384,759</u>
<b><u>Expenditure on:</u></b>					
Raising funds	6	4,958	-	4,958	8,336
Charitable activities	7	253,882	28,458	282,340	369,968
<b>Total resources expended</b>		<u>258,840</u>	<u>28,458</u>	<u>287,298</u>	<u>378,304</u>
<b>Net (expenditure)/income for the year/ Net movement in funds</b>		(34,986)	42,662	7,676	6,455
Fund balances at 1 October 2019		<u>424,430</u>	<u>40,981</u>	<u>465,411</u>	<u>458,956</u>
<b>Fund balances at 30 September 2020</b>		<u><u>389,444</u></u>	<u><u>83,643</u></u>	<u><u>473,087</u></u>	<u><u>465,411</u></u>

The statement of financial activities includes all gains and losses recognised in the year.

All income and expenditure derive from continuing activities.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
STATEMENT OF FINANCIAL POSITION**

**AS AT 30 SEPTEMBER 2020**

	Notes	2020 £	£	2019 £	£
<b>Current assets</b>					
Debtors	13	2,461		2,051	
Cash at bank and in hand		476,485		465,807	
		<u>478,946</u>		<u>467,858</u>	
<b>Creditors: amounts falling due within one year</b>	14	<u>(5,859)</u>		<u>(2,447)</u>	
Net current assets			<u>473,087</u>		<u>465,411</u>
<b>Income funds</b>					
Restricted funds	16		83,643		40,981
Unrestricted funds - general			389,444		424,430
			<u>473,087</u>		<u>465,411</u>

The financial statements were approved by the Trustees on .....

.....  
Mr P Gwilliam (Chairman)  
**Trustee**

# NEUROENDOCRINE CANCER UK PREVIOUSLY NET PATIENT FOUNDATION NOTES TO THE FINANCIAL STATEMENTS

**FOR THE YEAR ENDED 30 SEPTEMBER 2020**

---

## **1 Accounting policies**

### **Charity information**

Neuroendocrine Cancer UK is a unincorporated charity in England and Wales (charity number: 1092386) providing support and information to people affected by neuroendocrine cancers. The charity's address is: Second floor, Holly House, 74 Upper Holly Walk, Leamington Spa, Warwickshire, CV32 4JL.

### **1.1 Accounting convention**

The accounts have been prepared in accordance with the charity's constitution, the Charities Act 2011 and "Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and Republic of Ireland (FRS 102)" (as amended for accounting periods commencing from 1 January 2016). The charity is a Public Benefit Entity as defined by FRS 102.

The charity has taken advantage of the provisions in the SORP for charities applying FRS 102 Update Bulletin 1 not to prepare a Statement of Cash Flows.

The financial statements have departed from the Charities (Accounts and Reports) Regulations 2008 only to the extent required to provide a true and fair view. This departure has involved following the Statement of Recommended Practice for charities applying FRS 102 rather than the version of the Statement of Recommended Practice which is referred to in the Regulations but which has since been withdrawn.

The accounts are prepared in sterling, which is the functional currency of the charity. Monetary amounts in these financial statements are rounded to the nearest £1.

The financial statements have been prepared under the historical cost convention, modified to include the revaluation of freehold properties and to include investment properties and certain financial instruments at fair value. The principal accounting policies adopted are set out below.

### **1.2 Going concern**

The trustees have assessed the implications of the ongoing pandemic on the charity's ability to continue for the foreseeable future and believe that the charity has adequate reserves to meet costs where there is a reduction in income for a significant period in the future. Income for the first quarter of the current year is running at a level that substantiates this assessment.

### **1.3 Charitable funds**

Unrestricted funds are available for use at the discretion of the Trustees in furtherance of their charitable objectives.

Restricted funds are subject to specific conditions by donors as to how they may be used. The purposes and uses of the restricted funds are set out in the notes to the financial statements.

### **1.4 Income**

Income is recognised when the charity is legally entitled to it after any performance conditions have been met, the amounts can be measured reliably, and it is probable that income will be received.

Cash donations are recognised on receipt. Other donations are recognised once the charity has been notified of the donation (such as legacies), unless performance conditions require deferral of the amount. Income tax recoverable in relation to donations received under Gift Aid or deeds of covenant is recognised at the time of the donation on a receivable basis.

Legacies are recognised on receipt or otherwise if the charity has been notified of an impending distribution, the amount is known, and receipt is expected. If the amount is not known, the legacy is treated as a contingent asset.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

---

**1 Accounting policies**

**(Continued)**

**1.5 Expenditure**

Liabilities are recognised as expenditure as soon as there is a legal or constructive obligation committing the charity to that expenditure, it is probable that settlement will be required and the amount of the obligation can be measured reliably.

All expenditure is accounted for on an accruals basis. All expenses including support costs and governance costs are allocated or apportioned to the applicable expenditure headings.

Provisions for grants are made when the intention to make a grant has been communicated to the recipient but there is uncertainty as to the timing of the grant or the amount of grant payable.

**Costs of raising funds**

The costs of generating funds consist of investment management costs and certain legal fees.

Costs of charitable activities include grants made, governance costs and an apportionment of support costs and are shown in note 8.

Governance costs and support costs relating to charitable activities have been apportioned based on the number of individual grant awards made in recognition that the administrative costs of awarding, monitoring and assessing research grants, salary support grants are broadly equivalent. The allocation of support and governance costs is analysed in note 9.

Support costs have been allocated between governance costs and other support costs. Governance costs comprise all costs involving the public accountability of the charity and its compliance with regulation and good practice. These costs include costs related to statutory audit and legal fees together with relevant apportionment of overhead and support costs.

**1.6 Cash and cash equivalents**

Cash and cash equivalents include cash in hand, deposits held at call with banks, other short-term liquid investments with original maturities of three months or less, and bank overdrafts. Bank overdrafts are shown within borrowings in current liabilities.

**1.7 Financial instruments**

The charity has elected to apply the provisions of Section 11 'Basic Financial Instruments' and Section 12 'Other Financial Instruments Issues' of FRS 102 to all of its financial instruments.

Financial instruments are recognised in the charity's balance sheet when the charity becomes party to the contractual provisions of the instrument.

Financial assets and liabilities are offset, with the net amounts presented in the financial statements, when there is a legally enforceable right to set off the recognised amounts and there is an intention to settle on a net basis or to realise the asset and settle the liability simultaneously.

**Basic financial assets**

Basic financial assets, which include debtors and cash and bank balances, are initially measured at transaction price including transaction costs and are subsequently carried at amortised cost using the effective interest method unless the arrangement constitutes a financing transaction, where the transaction is measured at the present value of the future receipts discounted at a market rate of interest. Financial assets classified as receivable within one year are not amortised.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

---

**1 Accounting policies**

**(Continued)**

***Basic financial liabilities***

Basic financial liabilities, including creditors and bank loans are initially recognised at transaction price unless the arrangement constitutes a financing transaction, where the debt instrument is measured at the present value of the future payments discounted at a market rate of interest. Financial liabilities classified as payable within one year are not amortised.

Debt instruments are subsequently carried at amortised cost, using the effective interest rate method.

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of operations from suppliers. Amounts payable are classified as current liabilities if payment is due within one year or less. If not, they are presented as non-current liabilities. Trade creditors are recognised initially at transaction price and subsequently measured at amortised cost using the effective interest method.

***Derecognition of financial liabilities***

Financial liabilities are derecognised when the charity's contractual obligations expire or are discharged or cancelled.

**1.8 Employee benefits**

The cost of any unused holiday entitlement is recognised in the period in which the employee's services are received.

Termination benefits are recognised immediately as an expense when the charity is demonstrably committed to terminate the employment of an employee or to provide termination benefits.

**1.9 Retirement benefits**

Payments to defined contribution retirement benefit schemes are charged as an expense as they fall due.

**2 Critical accounting estimates and judgements**

In the application of the charity's accounting policies, the Trustees are required to make judgements, estimates and assumptions about the carrying amount of assets and liabilities that are not readily apparent from other sources. The estimates and associated assumptions are based on historical experience and other factors that are considered to be relevant. Actual results may differ from these estimates.

The estimates and underlying assumptions are reviewed on an ongoing basis. Revisions to accounting estimates are recognised in the period in which the estimate is revised where the revision affects only that period, or in the period of the revision and future periods where the revision affects both current and future periods.

**Critical judgements**

**Allocation of support costs**

Support costs have been allocated on a basis of estimation that the cost was incurred to support the charity's objectives. These judgements are made by the board of trustees to reflect the actual costs incurred in supporting the charity. See note 10 to the accounts which show the critical judgements made by the trustees and show the estimated costs that are deemed attributable to the charity's overheads.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

---

**3 Donations and legacies**

	<b>Unrestricted funds general 2020 £</b>	<b>Total 2019 £</b>
Donations and gifts	211,324	317,763
Legacies receivable	12,360	-
	<u>223,684</u>	<u>317,763</u>
	<u><u>223,684</u></u>	<u><u>317,763</u></u>

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 30 SEPTEMBER 2020**

**4 Grants**

	Ipsen	Merck	AAA	Lottery	Imaging Equipment	ITM	Victory Net	Total 2020	Total 2019
	2020	2020	2020	2020	2020	2020	2020		
	£	£	£	£	£	£	£	£	£
Performance related grants	9,800	-	43,827	7,500	-	9,993	-	71,120	66,846
Analysis by fund									
Unrestricted funds - general	-	-	-	-	-	-	-	-	17,310
Restricted funds	9,800	-	43,827	7,500	-	9,993	-	71,120	49,536
<b>For the year ended 30 September 2019</b>									
Unrestricted funds - general	-	-	-	-	2,310	-	15,000	-	17,310
Restricted funds	30,000	12,000	-	-	7,536	-	-	-	49,536
	30,000	12,000	-	-	9,846	-	15,000	-	66,846

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

---

**5 Investments**

	<b>Unrestricted funds general 2020 £</b>	<b>Total 2019 £</b>
Interest receivable	170	150
	<u>170</u>	<u>150</u>

**6 Raising funds**

	<b>Unrestricted funds general 2020 £</b>	<b>Total 2019 £</b>
<u>Fundraising and publicity</u>		
Other fundraising costs	4,958	8,336
	<u>4,958</u>	<u>8,336</u>
	<u>4,958</u>	<u>8,336</u>



**NEUROENDOCRINE CANCER UK**  
**PREVIOUSLY NET PATIENT FOUNDATION**  
**NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**  
**FOR THE YEAR ENDED 30 SEPTEMBER 2020**

**7 Charitable activities**

	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Staff costs	85,359	118,030
Charitable activities	62,208	67,494
Computer costs	1,973	1,818
Advertising and marketing	7,155	4,469
Travel and subsistence	5,055	9,308
Rent	9,057	10,413
Telephone	3,693	3,216
Office expenses	11,171	-
Legal and professional	3,300	-
Other costs	2,844	-
	<u>191,815</u>	<u>214,748</u>
Grant funding of activities (see note 9)	-	25,000
Share of support costs (see note 10)	84,914	123,592
Share of governance costs (see note 10)	5,611	6,628
	<u>282,340</u>	<u>369,968</u>
<b>Analysis by fund</b>		
Unrestricted funds - general	253,882	288,570
Restricted funds	28,458	81,398
	<u>282,340</u>	<u>369,968</u>
<b>For the year ended 30 September 2019</b>		
Unrestricted funds - general	288,570	
Restricted funds	81,398	
	<u>369,968</u>	

**8 Description of charitable activities**

Expenditure to support the primary activity

The charitable activities are to inform people to recognise, diagnose, treat, care for, and ultimately cure people with Neuroendocrine cancer. All activity costs above are the direct charitable costs in achieving these charitable objectives.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

---

<b>9 Grants payable</b>	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Oxford University vis UKINETS	-	25,000
	<u>          </u>	<u>          </u>
	-	25,000
	<u>          </u>	<u>          </u>

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 30 SEPTEMBER 2020**

**10 Support costs**

	Support costs	Governance costs	2020	2019	Basis of allocation
	£	£	£	£	
Staff costs	69,203	-	69,203	77,143	Administrative staff
Office expenses	2,793	-	2,793	27,141	20% of the cost (2019 100%)
Legal and professional	825	-	825	4,831	20% of the cost (2019 100%)
Computer costs	5,917	-	5,917	5,174	75% of the cost (2019 74%)
Rent and rates	3,882	-	3,882	2,603	30% of the cost (2019 20%)
Telecommunications	1,583	-	1,583	2,144	30% of the cost (2019 40%)
Other costs	711	-	711	4,556	20% of the cost (2019 100%)
Audit fees	-	4,228	4,228	5,394	Governance
Trustees expenses	-	1,383	1,383	1,234	Governance
	<u>84,914</u>	<u>5,611</u>	<u>90,525</u>	<u>130,220</u>	
Analysed between					
Charitable activities	<u>84,914</u>	<u>5,611</u>	<u>90,525</u>	<u>130,220</u>	

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
*FOR THE YEAR ENDED 30 SEPTEMBER 2020***

---

**10 Support costs**

**(Continued)**

Each member of staff has specific roles and responsibilities to fulfil and support the charity's objectives. Each member of staff is either allocated to frontline duties or placed in a supporting role which aids those staff to fulfil the charity's objectives.

Judgements are made by the trustees to allocate a percentage of resources to support costs that accurately reflect the time and resources spent in supporting the charities objectives. The estimation techniques can be seen in the note above and are specific to the charity's activities.

Governance costs include payments to the Independent Examiner of £1,872 (2019- £1,510) for the Independent Examination.

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

**11 Trustees**

None of the Trustees (or any persons connected with them) received any remuneration during the year or reimbursed expenses. In 2019, travelling expenses of £208 and meeting expenses of £881 were reimbursed to trustees.

During the year Trustees donated a total of £240 (2019 - £240) to general funds.

**12 Employees**

The average monthly number of employees during the year was:

	<b>2020</b>	<b>2019</b>
	<b>Number</b>	<b>Number</b>
	5	6
	<u>5</u>	<u>6</u>

**Employment costs**

	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Wages and salaries	141,337	177,212
Social security costs	9,970	14,561
Other pension costs	3,255	3,400
	<u>154,562</u>	<u>195,173</u>

**13 Debtors**

	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
<b>Amounts falling due within one year:</b>		
Other debtors	2,461	2,051
	<u>2,461</u>	<u>2,051</u>

**14 Creditors: amounts falling due within one year**

	<b>2020</b>	<b>2019</b>
	<b>£</b>	<b>£</b>
Other taxation and social security	2,482	-
Other creditors	1,505	937
Accruals and deferred income	1,872	1,510
	<u>5,859</u>	<u>2,447</u>

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

---

**15 Retirement benefit schemes**

**Defined contribution schemes**

The charity operates a defined contribution pension scheme for all qualifying employees. The assets of the scheme are held separately from those of the charity in an independently administered fund.

The charge to profit or loss in respect of defined contribution schemes was £3,255 (2019:£3,400).

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)**

**FOR THE YEAR ENDED 30 SEPTEMBER 2020**

**16 Restricted funds**

The income funds of the charity include restricted funds comprising the following unexpended balances of donations and grants held on trust for specific purposes:

	Movement in funds			Movement in funds			
	Balance at 1 October 2018	Incoming resources	Resources expended	Balance at 1 October 2019	Incoming resources	Resources expended	Balance at 30 September 2020
	£	£	£	£	£	£	£
IEL/Novartis - Data Coding Project	27,000	-	(27,000)	-	-	-	-
IEL - App Project	45,843	15,000	(34,862)	25,981	-	(10,800)	15,181
MCC	-	12,000	(12,000)	-	-	-	-
Office Equipment	-	7,536	(7,536)	-	-	-	-
Ipsen - Publicity/PR	-	15,000	-	15,000	-	(11,665)	3,335
AAA - Data Extraction / Medical Writing Project	-	-	-	-	14,000	-	14,000
AAA - NCUK Summit	-	-	-	-	8,500	-	8,500
AAA - Nurse Course	-	-	-	-	9,800	-	9,800
AAA - Patient Travel / Welfare Support	-	-	-	-	5,000	-	5,000
AAA - Psychological Support	-	-	-	-	6,527	-	6,527
Ipsen -Nurse Course	-	-	-	-	9,800	-	9,800
ITM - Mind the Gap Project	-	-	-	-	9,993	(5,993)	4,000
Lottery - Psychological Support	-	-	-	-	7,500	-	7,500
	<u>72,843</u>	<u>49,536</u>	<u>(81,398)</u>	<u>40,981</u>	<u>71,120</u>	<u>(28,458)</u>	<u>83,643</u>

**NEUROENDOCRINE CANCER UK  
PREVIOUSLY NET PATIENT FOUNDATION  
NOTES TO THE FINANCIAL STATEMENTS (CONTINUED)  
FOR THE YEAR ENDED 30 SEPTEMBER 2020**

**17 Analysis of net assets between funds**

	Unrestricted funds 2020 £	Restricted funds 2020 £	Total 2020 £	Total 2019 £
Fund balances at 30 September 2020 are represented by:				
Current assets/(liabilities)	389,444	83,643	473,087	465,411
	<u>389,444</u>	<u>83,643</u>	<u>473,087</u>	<u>465,411</u>

**18 Related party transactions**

**Remuneration of key management personnel**

The remuneration of key management personnel is as follows.

	2020 £	2019 £
Aggregate compensation	59,192	52,480
	<u>59,192</u>	<u>52,480</u>